news

Novel DNA vaccine offers broad protection against Influenza-A H3N

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses…

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades. The DNA vaccine protected mice against a lethal challenge with more than one influenza-A H3N2 virus and protected them from severe H3N2-related illness despite the lack of an exact sequence match between the vaccine immunogen and H3 immunogen. 

David Weiner, The Wistar Institute of Anatomy & Biology, Philadelphia, PA, and coauthors from Wistar and Inovio Pharmaceuticals, Plymouth Meeting, PA conducted the study entitled “A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.” This new DNA vaccine strategy was intended to elicit a comprehensive immune response and to represent a step forward in eliminating the need to reformulate a seasonal vaccine each year to protect against influenza-A H3N2.

The researchers designed a vaccine designed to elicit broad immune responses against diverse influenza-A H3N2 viruses by engineering four synthetic hemagglutinin H3 immunogens. The H3 sequences used were chosen by aligning sequences from 233 influenza-A H3N2 strains representing viruses from across multiple decades. The researchers identified four micro-consensus sequences with sufficient sequence similarity to predict cross-reactive immune responses against diverse H3N2 strains.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

“Influenza continues to be a major cause of morbidity and mortality worldwide, as the virus continuously changes to evade the human immune system,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. “The approach developed by the Wistar Institute team holds great promise as a means to elicit an immune response that the virus will not evade.”

The findings are reported in Human Gene Therapy.

Related topics
, ,

Related conditions

Leave a Reply

Your email address will not be published. Required fields are marked *